2-bromo-3-cyclopentylthiophene | 1034138-14-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 2-bromo-3-cyclopentylthiophene
• CAS: 1034138-14-1
• 化学式: C₉H₁₁BrS
• 分子量: 231.156
• InChiKey: PETWQTQXPOSNAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-3-cyclopentylthiophene 、 9-芴酮 生成 9-(3-cyclopentylthien-2-yl)-9H-fluoren-9-ol
  参考文献：
  名称：

  Tricylic amino-acid derivatives

  摘要：

  本文描述了具有以下一般式的化合物：##STR1##或其前药或药用可接受的盐、溶剂或水合物，其中：R.sup.1选自H、烷基和碱性加成盐的对离子组成的群；X选自CR.sup.9 R.sup.10、S、O、SO、SO.sub.2、NH和N-烷基的群；R.sup.2、R.sup.3、R.sup.4、R.sup.9和R.sup.10独立地选自H和烷基的群；R.sup.5和R.sup.6独立地选自H、烷基和苯基，或者，作为另一选择，R.sup.5和R.sup.6可以一起形成亚甲基基团或3-至6-成员的螺环基团；当X为CR.sup.9 R.sup.10时，R.sup.5和R.sup.9或R.sup.6和R.sup.10中的一个或两个对可能连接以形成双键或三键R.sup.7选自以下式II-V的群：##STR2##它们都可以在除R.sup.8之外的节点上选择性地取代，取代基独立地选自烷基、卤素、芳基（可能像R.sup.8那样被取代）、三氟甲基、三氟甲氧基、硝基、氰基、氨基、单烷基氨基、双烷基氨基、烷氧羰基、烷基羰基、烷氧硫代羰基、烷基硫代羰基、烷氧基、烷基硫、苯氧基、--SO.sub.2 NH.sub.2、--SO.sub.2 NH烷基、--SO.sub.2 N(烷基).sub.2和1,2-亚甲二氧基；结构II至V中的苯并环中的任何一个都可以被选择自吡啶、噻吩、呋喃和吡咯的5-或6-成员杂环环取代；其中R.sup.8选自H、烷基、苄基、环烷基、茚基和一个可选择性取代的芳基，其中可选择性取代基独立地选自烷基、卤素、芳基、三氟甲基、三氟甲氧基、硝基、氰基、氨基、单烷基氨基、双烷基氨基、烷氧羰基、烷基羰基、烷氧硫代羰基、烷基硫代羰基、烷氧基、烷基硫、苯氧基、--SO.sub.2 NH.sub.2、--SO.sub.2 NH烷基、--SO.sub.2 N(烷基).sub.2和1,2-亚甲二氧基；--表示单键或双键；Y选自O、S、SO、NH、N-烷基、CH.sub.2、CH-烷基、C(烷基).sub.2和C.dbd.O的群；当--为单键时，Z选自CH.sub.2、O、S、NH和N-烷基的群；当--为双键时，Z选自CH和N的群。还描述了这些化合物作为药物的用途。

  公开号：

  US06162824A1
• 作为产物：
  描述：

  3-环戊基噻吩 在 N-溴代丁二酰亚胺(NBS) 、 sodium thiosulfate 、 potassium iodide 作用下， 以 氯仿 、 溶剂黄146 为溶剂， 反应 3.0h， 以83%的产率得到2-bromo-3-cyclopentylthiophene
  参考文献：
  名称：

  用于多相不对称 Hetero-Diels-Alder 反应的基于铬-噻吩-salen 的聚合物

  摘要：

  已经合成了新的手性噻吩-salen 配体，并且相应的铬配合物被证明是促进不对称杂 Diels-Alder 反应的有效催化剂，具有良好的活性和高对映选择性（高达 88% ee）。这些配合物被成功地电聚合得到手性聚合物，作为不溶性粉末用于不对称多相催化。当进行连续的异-Diels-Alder 反应时，他们以高产率和对映选择性提供了预期的产物，在长达 15 次循环中没有效率损失。手性铬-salen-噻吩聚合物也成功地用于多底物程序，在该程序中，每次重复使用时都会引入结构不同的新醛，以提供纯形式的所需吡喃酮。(© Wiley-VCH Verlag GmbH & Co. KGaA,

  DOI：

  10.1002/ejoc.200701218

文献信息

• Chromium-Thiophene-salen-Based Polymers for Heterogeneous Asymmetric Hetero-Diels–Alder Reactions
  作者：Anaïs Zulauf、Mohamed Mellah、Régis Guillot、Emmanuelle Schulz

  DOI：10.1002/ejoc.200701218

  日期：2008.4

  proved to beefficient catalysts for promoting asymmetric hetero-Diels–Alder reactions with good activities and high enantioselectivities (up to 88 % ee). These complexes were successfully electropolymerized to give chiral polymers as insoluble powders for use in asymmetric heterogeneous catalysis. When engaged in successive hetero-Diels–Alder reactions, they afforded the expected products in high yield

  已经合成了新的手性噻吩-salen 配体，并且相应的铬配合物被证明是促进不对称杂 Diels-Alder 反应的有效催化剂，具有良好的活性和高对映选择性（高达 88% ee）。这些配合物被成功地电聚合得到手性聚合物，作为不溶性粉末用于不对称多相催化。当进行连续的异-Diels-Alder 反应时，他们以高产率和对映选择性提供了预期的产物，在长达 15 次循环中没有效率损失。手性铬-salen-噻吩聚合物也成功地用于多底物程序，在该程序中，每次重复使用时都会引入结构不同的新醛，以提供纯形式的所需吡喃酮。(© Wiley-VCH Verlag GmbH & Co. KGaA,
• US6162824A
  申请人：——

  公开号：US6162824A

  公开（公告）日：2000-12-19
• [EN] TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS<br/>[FR] COMPOSES TRICYCLIQUES COMME INHIBITEURS DE TRANSPORT DE GLYCINE
  申请人：ALLELLIX NEUROSCIENCE INC

  公开号：WO2001009117A1

  公开（公告）日：2001-02-08

  Described herein are compounds which have general formula (I) or a prodrug or pharmaceutically acceptable salt, solvate or hydrate thereof wherein R1 is selected from the group consisting of H, alkyl and the counter ion for a basic addition salt; R?2, R3, R4, R9 and R10¿ are independently selected from the group consisting of H and alkyl; R?5 and R6¿ are independently selected from the group consisting of H, alkyl and phenyl; X is selected from the group consisting of CR9R10, S, O, SO, SO¿2?, NH and N-alkyl; R?7¿ is selected from the group consisting of Formula (II-V), wherein at least one of the benzo-fused rings in structures (II-V) is replaced by a 5- or 6-membered heterocyclic ring selected from the group consisting of pyridine, thiophene, furan and pyrrole; wherein the groups of Formula (II) to (V) are optionally substituted, at nodes other than R8, with 1-4 substituents independently selected from the group consisting of alkyl, halo, aryl (which may be substituted as for R8), trifluomethyl, trifluoromethoxy, nitro, cyano, amino, mono-alkylamino, di-alkylamino, alkoxycarbonyl, alkylcarbonyl, alkoxythiocarbonyl, alkylthiocarbonyl, alkoxy, alkylS-, phenoxy, -SO¿2?NH2,-SO2NHalkyl-SO2N(alkyl)2 and 1,2-methylenedioxy; and wherein R?8¿ is selected from the group consisting of H, alkyl, benzyl, cycloalkyl, indanyl and an optionally substituted aryl group, wherein the optional substituents are independently selected from 1-4 members of the group consisting of alkyl, halo, aryl, trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, mono-alkylamino, di-alkylamino, alkoxycarbonyl, alkylcarbonyl, alkoxythiocarbonyl, alkythiocarbonyl, alkoxy, alkylS-, phenoxy, -SO¿2?NH2, -SO2NHalkyl,- SO2N(alkyl)2 and 1,2-methylenedioxy; ----- represents a single or double bond; Y is selected from the group consisting of O, S, SO, NH, N-alkyl, CH2, CH-alkyl, C(alkyl)2, and C=O; Z is selected from the group consisting of CH2, O,S, NH and N-alkyl when ----- is a single bond; Z is selected from the group consisting of CH and N when ----- is a double bond. Also described is the use of these compounds as pharmaceuticals.
• Tricylic amino-acid derivatives
  申请人：Allelix Neuroscience Inc.

  公开号：US06162824A1

  公开（公告）日：2000-12-19

  Described herein are compounds which have the general formula: ##STR1## or a prodrug or pharmaceutically acceptable salt, solvate or hydrate thereof wherein: R.sup.1 is selected from the group consisting of H, alkyl and the counter ion for a basic addition salt; X is selected from the group consisting of CR.sup.9 R.sup.10, S, O, SO, SO.sub.2, NH and N-alkyl; R.sup.2, R.sup.3, R.sup.4, R.sup.9 and R.sup.10 are independently selected from the group consisting of H and alkyl; R.sup.5 and R.sup.6 are independently selected from the group consisting of H, alkyl and phenyl, or, alternatively, R.sup.5 and R.sup.6 together may form a methylene group or a 3- to 6-membered a spirocyclic group; wherein, when X is CR.sup.9 R.sup.10, one or both pairs of R.sup.5 and R.sup.9 or R.sup.6 and R.sup.10 may join to form a double or triple bond R.sup.7 is selected from the group consisting of Formula II-V: ##STR2## which are all optionally substituted, at nodes other than R.sup.8, with 1-4 substituents independently selected from the group consisting of alkyl, halo, aryl (which may be substituted as for R.sup.8), trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, mono-alkylamino, di-alkylamino, alkoxycarbonyl, alkylcarbonyl, alkoxythiocarbonyl, alkylthiocarbonyl, alkoxy, alkylS-, phenoxy, --SO.sub.2 NH.sub.2, --SO.sub.2 NHalkyl, --SO.sub.2 N(alkyl).sub.2 and 1,2-methylenedioxy; and wherein any of the benzo-fused rings in structures II to V may be replaced by a 5- or 6-membered heterocyclic ring selected from the group consisting of pyridine, thiophene, furan and pyrrole; wherein R.sup.8 is selected from the group consisting of H, alkyl, benzyl, cycloalkyl, indanyl and an optionally substituted aryl group, wherein the optional substituents are independently selected from 1-4 members of the group consisting of alkyl, halo, aryl, trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, mono-alkylamino, di-alkylamino, alkoxycarbonyl, alkylcarbonyl, alkoxythiocarbonyl, alkylthiocarbonyl, alkoxy, alkylS-, phenoxy, --SO.sub.2 NH.sub.2, --SO.sub.2 NHalkyl, --SO.sub.2 N(alkyl).sub.2 and 1,2-methylenedioxy; --represents a single or double bond; Y is selected from the group consisting of O, S, SO, NH, N-alkyl, CH.sub.2, CH-alkyl, C(alkyl).sub.2, and C.dbd.O; Z is selected from the group consisting of CH.sub.2, O, S, NH and N-alkyl when--is a single bond; Z is selected from the group consisting of CH and N when--is a double bond. Also described is the use of these compounds as pharmaceuticals.

  本文描述了具有以下一般式的化合物：##STR1##或其前药或药用可接受的盐、溶剂或水合物，其中：R.sup.1选自H、烷基和碱性加成盐的对离子组成的群；X选自CR.sup.9 R.sup.10、S、O、SO、SO.sub.2、NH和N-烷基的群；R.sup.2、R.sup.3、R.sup.4、R.sup.9和R.sup.10独立地选自H和烷基的群；R.sup.5和R.sup.6独立地选自H、烷基和苯基，或者，作为另一选择，R.sup.5和R.sup.6可以一起形成亚甲基基团或3-至6-成员的螺环基团；当X为CR.sup.9 R.sup.10时，R.sup.5和R.sup.9或R.sup.6和R.sup.10中的一个或两个对可能连接以形成双键或三键R.sup.7选自以下式II-V的群：##STR2##它们都可以在除R.sup.8之外的节点上选择性地取代，取代基独立地选自烷基、卤素、芳基（可能像R.sup.8那样被取代）、三氟甲基、三氟甲氧基、硝基、氰基、氨基、单烷基氨基、双烷基氨基、烷氧羰基、烷基羰基、烷氧硫代羰基、烷基硫代羰基、烷氧基、烷基硫、苯氧基、--SO.sub.2 NH.sub.2、--SO.sub.2 NH烷基、--SO.sub.2 N(烷基).sub.2和1,2-亚甲二氧基；结构II至V中的苯并环中的任何一个都可以被选择自吡啶、噻吩、呋喃和吡咯的5-或6-成员杂环环取代；其中R.sup.8选自H、烷基、苄基、环烷基、茚基和一个可选择性取代的芳基，其中可选择性取代基独立地选自烷基、卤素、芳基、三氟甲基、三氟甲氧基、硝基、氰基、氨基、单烷基氨基、双烷基氨基、烷氧羰基、烷基羰基、烷氧硫代羰基、烷基硫代羰基、烷氧基、烷基硫、苯氧基、--SO.sub.2 NH.sub.2、--SO.sub.2 NH烷基、--SO.sub.2 N(烷基).sub.2和1,2-亚甲二氧基；--表示单键或双键；Y选自O、S、SO、NH、N-烷基、CH.sub.2、CH-烷基、C(烷基).sub.2和C.dbd.O的群；当--为单键时，Z选自CH.sub.2、O、S、NH和N-烷基的群；当--为双键时，Z选自CH和N的群。还描述了这些化合物作为药物的用途。
• Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization
  作者：Daniel K. Whelligan、Savade Solanki、Dawn Taylor、Douglas W. Thomson、Kwai-Ming J. Cheung、Kathy Boxall、Corine Mas-Droux、Caterina Barillari、Samantha Burns、Charles G. Grummitt、Ian Collins、Rob L. M. van Montfort、G. Wynne Aherne、Richard Bayliss、Swen Hoelder

  DOI：10.1021/jm1008727

  日期：2010.11.11

  We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2. Starting from HTS hit aminopyrazine 2, compounds with improved activity were identified using structure-based design. Our structural biology investigations reveal two notable observations. First, 2 and related compounds bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors. Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein. The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.